One case of acute constipation induced by semaglutide injection

doi:10.19803/j.1672-8629.20220584

Abstract

Abstract: Objective To recommend measures of pharmacovigilance of semaglutide injection based on one case of acute constipation. Methods One case of acute constipation after semaglutide injection was analyzed, and a proper medication was recommended. Results The patient started with 0.5 mg semaglutide injection, but developed acute constipation symptoms the next day. After symptomatic treatment, the constipation symptoms were alleviated. After the dosage was reduced, constipation did not re-occur. Given the correlations between the patient’s clinical manifestations and the time of administration, the acute constipation was believed to have been caused by semaglutide injection. Conclusion Semaglutide injection is used for weight loss, which is off-label, so large doses may cause acute constipation. Clinicians are recommended to start with small doses according to the instructions, and inform the patients of possible adverse reactions. In case of adverse reactions, emergency medical treatment should be offered.

Key words: semaglutide, injection, acute constipation, adverse drug reaction, off-label use

CLC Number:

QIN Guilan, ZHOU Muzi, JI Zhaoshuai, MAO Qiantai, AI Chao. One case of acute constipation induced by semaglutide injection[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 833-835.

References

[1] Chinese Diabetes Society.Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Chinese Journal of Diabetes(中华糖尿病杂志),2021,13(4):315-409.
[2] HAN MF,ZHAO B,CHEN W,et al.The mechanism and clinical application of semaglutide in obesity[J]. Chinese Journal of New Drugs(中国新药杂志),2022,31(9):859-862.
[3] JI LN,ZHOU DJ,HONG TP,et al.Expert guidance on clinical application of GLP-1 receptor agonist[J]. Chinese Journal of Diabetes(中国糖尿病杂志),2018,26(5):353-361.
[4] WADDEN TA,BAILEY TS,BILLINGS LK,et al.Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the step 3 randomized clinical trial[J]. Journal of the American Medical Association,2021,325(14):1403-1413.
[5] WILDING JPH,BATTERHAM RL,CALANNA S,et al.Once-weekly semaglutide in adults with overweight or obesity[J]. The New England Journal of Medicine,2021,384(11):989-1002.
[6] RUBINO DM,GREENWAY FL,KHALID U,et al.Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial[J]. Journal of the American Medical Association,2022,327(2):138-150.
[7] LEEHEY DJ,RAHMAN MA,BOTYSE, et al. Acute kidney injuryassociated with semaglutide[J]. Kidney Medicine,2021,3(2):282-285.
[8] ENSLIN S, BARTELL N, KAUL V.The first reported case of drug-induced liver injury caused by semaglutide[J]. American Journal of Gastroenterology,2021,116:S1141.
[9] FARASAT S,MCCALLUM J.Semaglutide-induced leukocytoclastic vasculitis[J]. Endocrine Practice,2022,28(2):S21-S22.
[10] Drug Safety Supervision Department of State Food and Drug Administration, National Center for Adverse Drug Reaction. Manual for adverse drug reaction reporting and monitoring[S]. Being, 2012: 49.
[11] Gastrointestinal Dynamics Group,Society of Digestive Diseases,Chinese Medical Association.Colorectal and Anorectal Surgery Group,Surgical Society of Chinese Medical Association.Guidelines for the diagnosis and treatment of chronic constipation in China(Wuhan,2013)[J].Chinese Journal of Digestion(中华消化杂志),2013,33(5):291-297.
[12] YE GF.Diagnosis and treatment of drug-induced constipation[J]. Journal of North Pharmacy(北方药学),2013,10(10):21.
[13] FRIEDRICHSEN M,BREITSCHAFT A,TADAYON S,et al.The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating and gastric emptying in adults with obesity[J]. Diabetes,Obesity and Metabolism,2021,23(3):754-762.
[14] HALIM A,DEGERBLAD M,SUNDBOM M,et al.Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans[J]. The Journal of Clinical Endocrinology and Metabolism,2018,103(2):575-585.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[3]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[4]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[5]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[6]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[7]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[8]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[9]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[10]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[11]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[12]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[13]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[14]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[15]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.